Prevention of cervical, vaginal, and vulval cancers: role of the quadrivalent human papillomavirus (6, 11, 16, 18) recombinant vaccine
Maria Lina DiazSection of Ambulatory Gynecology Cleveland Clinic Florida Weston, Florida, USAAbstract: The relationship between the human papillomavirus (HPV) and malignancies of the uterine cervix, vagina, and vulva has been established. The development of a quadrivalent HPV recombinant prophylacti...
Saved in:
Main Author: | Maria Lina Diaz (Author) |
---|---|
Format: | Book |
Published: |
Dove Medical Press,
2009-09-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
A novel vaccine for cervical cancer: quadrivalent human papillomavirus (types 6, 11, 16 and 18) recombinant vaccine (Gardasil®)
by: Vandana A Govan
Published: (2008) -
GARDASIL. QUADRIVALENT RECOMBINANT VACCINE AGAINST HPV (6, 11, 16, 18 TYPES)
by: article editorial
Published: (2007) -
GARDASIL. QUADRIVALENT RECOMBINANT VACCINE AGAINST HPV (6, 11, 16, 18 TYPES)
by: article editorial
Published: (2007) -
Safety of human papillomavirus 6, 11, 16 and 18 (recombinant): systematic review and meta-analysis
by: Pedro Luiz Spinelli Coelho, et al.
Published: (2015) -
Cost-effectiveness analysis of AS04-adjuvanted human papillomavirus 16/18 vaccine compared with human papillomavirus 6/11/16/18 vaccine in the Philippines, with the new 2-dose schedule
by: Maria Julieta Germar, et al.
Published: (2017)